Compare Ascendis Pharma A/S (ASND) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Colgate-Palmolive Company — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Colgate-Palmolive Company trades at $92.91 (market cap $73.81B). The key difference: Colgate-Palmolive Company is far larger — about 4.2× Ascendis Pharma A/S's market cap, and Colgate-Palmolive Company pays a 2.3% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CL | |
|---|---|---|
Market Cap | $17.74B | $73.81B |
Sector | Health | Consumer Staples |
52-Week High | $277.18 | $99.14 |
52-Week Low | $163.32 | $74.98 |
Enterprise Value | $18.11B | $80.45B |
Dividend Yield | — | 2.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Colgate-Palmolive (CL) trades at $92.24, up 1.35% on the day, reflecting strong momentum with a bullish technical signal and consistent earnings beats. The company maintains robust profitability with a 60.06% gross margin and 10.04% net income margin, though its P/E of 35.75 and P/B of 509.03 indicate premium valuation. Recent news highlights its status as a Dividend King with a 64-year streak, supported by stable cash flow from operations of $4.20B in 2025.
Outlook remains positive with analyst consensus target of $95.56, but risks include North American segment softness and inflationary pressures. The stock offers income stability through dividends, yet high valuation multiples may limit near-term upside absent accelerated growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
